In a report released today, Alexander Nowak from Craig-Hallum maintained a Buy rating on Bioventus (BVS – Research Report). The company’s shares closed last Friday at $0.98.
Nowak covers the Healthcare sector, focusing on stocks such as CVRx, NeoGenomics, and REPRO-MED Systems. According to TipRanks, Nowak has an average return of -5.7% and a 39.20% success rate on recommended stocks.
Currently, the analyst consensus on Bioventus is a Moderate Buy with an average price target of $3.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $10.02 and a one-year low of $0.80. Currently, Bioventus has an average volume of 1.42M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bioventus Inc is a medical technology company incorporated in Delaware on December 22, 2015. The Company is engaged in developing and commercializing orthobiologic products for the treatment of patients suffering from a broad array of musculoskeletal conditions. Its products address the growing need for clinically effective, cost efficient and minimally invasive solutions that enhance the body’s natural healing processes. The Company operates through four segments including Active Healing Therapies-U.S., Active Healing Therapies-International, Surgical and BMP. The Company’s Active Healing Therapies segments offer two types of non-surgical products including non-invasive Exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief.
Read More on BVS:
- Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023
- Bioventus Announces CEO Leadership Change
- Bioventus announces CEO Realji has stepped down from position
- Bioventus price target lowered to $5 from $10 at Craig-Hallum
- Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results
